The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Developments in Viral Vector-Based Vaccines
Open accessAbstract
Viral vectors are promising tools for gene therapy and vaccines. Viral vector-based vaccines can enhance immunogenicity without an adjuvant and induce a robust cytotoxic T lymphocyte (CTL) response to eliminate virus-infected cells. During the last several decades, many types of viruses have been developed as vaccine vectors. Each has unique features and parental virus-related risks. In addition, genetically altered vectors have been developed to improve efficacy and safety, reduce administration dose, and enable large-scale manufacturing. To date, both successful and unsuccessful results have been reported in clinical trials. These trials provide important information on factors such as toxicity, administration dose tolerated, and optimized vaccination strategy. This review highlights major viral vectors that are the best candidates for clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Bartholomae, C. C., Ranzani, M., Benedicenti, F., Sergi, L. S., Ambrosi, A., Ponzoni, M., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37630 · Cited by 571
Gene therapy vectors based on adeno-associated virus type 1
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., & Wilson, J. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3994-4003.1999 · Cited by 541
AAV hybrid serotypes: improved vectors for gene delivery
Choi, V., McCarty, D., & Samulski, R. (2005) · Current Gene Therapy · doi:10.2174/1566523054064968 · Cited by 191
Nakanishi, M., & Otsu, M. (2012) · Current Gene Therapy · doi:10.2174/156652312802762518 · Cited by 147
Immune responses to AAV-vectors, the Glybera example from bench to bedside
Ferreira, V., Petry, H., & Salmon, F. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00082 · Cited by 120
Xin, K.-Q., Mizukami, H., Urabe, M., Toda, Y., Shinoda, K., Yoshida, A., Oomura, K., Kojima, Y., Ichino, M., Klinman, D., et al. (2006) · Journal of Virology · doi:10.1128/jvi.00890-06 · Cited by 81
Self-citationNieto, K., Stahl-Hennig, C., Leuchs, B., Müller, M., Gissmann, L., & Kleinschmidt, J. A. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.202 · Cited by 46
Cited by
COVID-19 Vaccine: A comprehensive status report
Kaur, S. P., & Gupta, V. (2020) · Virus Research · doi:10.1016/j.virusres.2020.198114 · Cited by 852
The Limitless Future of RNA Therapeutics
Damase, T. R., Sukhovershin, R., Boada, C., Taraballi, F., Pettigrew, R. I., & Cooke, J. P. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.628137 · Cited by 544
The 60-year evolution of lipid nanoparticles for nucleic acid delivery
Cullis, P. R., & Felgner, P. L. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00977-6 · Cited by 503
COVID-19 vaccines: The status and perspectives in delivery points of view
Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375
COVID-19 Vaccine Frontrunners and Their Nanotechnology Design
Chung, Y. H., Beiss, V., Fiering, S. N., & Steinmetz, N. F. (2020) · ACS Nano · doi:10.1021/acsnano.0c07197 · Cited by 346
Metadata
- Authors
- Ura, T., Okuda, K., & Shimada, M.
- Venue
- Vaccines
- Publisher
- MDPI AG
- Published
- 2014-07-29
- Volume
- 2
- Issue
- 3
- Pages
- 624-641
- ISSN
- 2076-393X (ISSN-L)
- OpenAlex
- W2166737662
- Cited by
- 436
- References
- 8
- FWCI
- 8.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Developments in Viral Vector-Based Vaccines. https://app.cochat.ai/papers/10.3390/vaccines2030624
- The paper
- Ura, T., Okuda, K., & Shimada, M. (2014). Developments in Viral Vector-Based Vaccines. Vaccines. https://doi.org/10.3390/vaccines2030624
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
